Emcure Pharma shares in focus as Bain Capital likely to offload 2.4% stake via block deal

Emcure Pharmaceuticals shares will be in focus on Friday following reports that Bain Capital-affiliated entity BC Investments IV is likely to offload a 2.4% stake in the company via a block deal worth Rs 551 crore.

The transaction will involve 45.5 lakh shares at a floor price of Rs 1,279.80 apiece, marginally below Thursday’s close of Rs 1,280.30. Kotak Securities is acting as the lead manager for the deal, sources told media outlets.

Also Read: Suzlon, Adani Ports among 10 stocks that earned upgrades in last 1 month. Check revised target price


Emcure reported a 63% year-on-year jump in consolidated net profit to Rs 197 crore for the March quarter, while revenue rose 19.5% YoY to Rs 2,116 crore, driven by strong performance in both domestic and international markets.

Despite the robust financials, the stock has seen muted action recently. Emcure shares are down 4% in the past month and nearly 13% year-to-date (YTD). The stock is trading 19% below its all-time high of Rs 1,580, hit in September 2024.

Emcure listed in July 2024, raising Rs 1,952 crore through an IPO, which included a fresh issue of Rs 800 crore and an OFS of Rs 1,151 crore. Priced at Rs 1,008 per share, the stock currently trades about 27% above its IPO price.

Also Read: 10 Nifty smallcaps with up to 29 buy calls; analysts see up to 26% upside

Emcure Pharma share price target

According to Trendlyne, the average target price for Emcure Pharma is Rs 1,458, implying an upside of 14% from current levels. Among the three analysts covering the stock, the consensus rating is ‘Buy’.

The stock's Relative Strength Index (RSI) stands at 47.6, indicating neutral momentum. It trades above its 50-day, 100-day, and 200-day moving averages, but remains below its 20-day and 30-day SMAs.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)